1
|
Dong T, Liang Y, Chen H, Li Y, Li Z, Gao X. Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion. J Proteomics 2024; 302:105201. [PMID: 38768894 DOI: 10.1016/j.jprot.2024.105201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 05/15/2024] [Accepted: 05/17/2024] [Indexed: 05/22/2024]
Abstract
To identify protein biomarkers capable of early prediction regarding the distinguishing malignant pleural effusion (MPE) from benign pleural effusion (BPE) in patients with lung disease. A four-dimensional data independent acquisition (4D-DIA) proteomic was performed to determine the differentially expressed proteins in samples from 20 lung adenocarcinoma MPE and 30 BPE. The significantly differential expressed proteins were selected for Gene Ontology (GO) enrichment and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis. Protein biomarkers with high capability to discriminate MPE from BPE patients were identified by Random Forest (RF) algorithm prediction model, whose diagnostic and prognostic efficacy in primary tumors were further explored in public datasets, and were validated by ELISA experiment. 50 important proteins (30 up-regulated and 20 down-regulated) were selected out as potential markers to distinguish the MPE from BPE group. GO analysis revealed that those proteins involving the most important cell component is extracellular space. KEGG analysis identified the involvement of cellular adhesion molecules pathway. Furthermore, the Area Under Curve (AUC) of these proteins were ranged from 0.717 to 1.000,with excellent diagnostic properties to distinguish the MPE. Finally, significant survival and gene and protein expression analysis demonstrated BPIFB1, DPP4, HPRT1 and ABI3BP had high discriminating values. SIGNIFICANCE: We performed a 4D-DIA proteomics to determine the differentially expressed proteins in pleural effusion samples from MPE and BPE. Some potential protein biomarkers were identified to distinguish the MPE from BPE patients., which may provide helpful diagnostic and therapeutic insights for lung cancer. This is significant because the median survival time of patients with MPE is usually 4-12 months, thus, it is particularly important to diagnose MPE early to start treatments promptly. The most common causes of MPE are lung cancers, while pneumonia and tuberculosis are the main causes of BPE. If more diagnostic markers could be identified periodically, there would be an important significance to clinical diagnose and treatment with drugs in lung cancer patients.
Collapse
Affiliation(s)
- Tingyan Dong
- School of Medicine, Nanjing University, Nanjing, Jiangsu, China; Guangzhou Huayin Medical Laboratory Center, Guangzhou, Guangdong, China
| | - Yueming Liang
- Department of Respiratory and Critical Care Medicine, The First People's Hospital of Foshan, Foshan, Guangdong, China; Department of Geriatric Respiratory Medicine, Guangdong Provincial Geriatrics Institute,Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China
| | - Hui Chen
- Guangzhou Huayin Medical Laboratory Center, Guangzhou, Guangdong, China
| | - Yanling Li
- Guangzhou Huayin Medical Laboratory Center, Guangzhou, Guangdong, China
| | - Zhiping Li
- Shanghai Pudong New District Zhoupu Hospital, Shanghai, China
| | - Xinglin Gao
- Department of Geriatric Respiratory Medicine, Guangdong Provincial Geriatrics Institute,Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
| |
Collapse
|
4
|
Hernández ÁP, Micaelo A, Piñol R, García-Vaquero ML, Aramayona JJ, Criado JJ, Rodriguez E, Sánchez-Gallego JI, Landeira-Viñuela A, Juanes-Velasco P, Díez P, Góngora R, Jara-Acevedo R, Orfao A, Miana-Mena J, Muñoz MJ, Villanueva S, Millán Á, Fuentes M. Comprehensive and systematic characterization of multi-functionalized cisplatin nano-conjugate: from the chemistry and proteomic biocompatibility to the animal model. J Nanobiotechnology 2022; 20:341. [PMID: 35858906 PMCID: PMC9301860 DOI: 10.1186/s12951-022-01546-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 07/05/2022] [Indexed: 11/16/2022] Open
Abstract
Background Nowadays, nanoparticles (NPs) have evolved as multifunctional systems combining different custom anchorages which opens a wide range of applications in biomedical research. Thus, their pharmacological involvements require more comprehensive analysis and novel nanodrugs should be characterized by both chemically and biological point of view. Within the wide variety of biocompatible nanosystems, iron oxide nanoparticles (IONPs) present mostly of the required features which make them suitable for multifunctional NPs with many biopharmaceutical applications. Results Cisplatin-IONPs and different functionalization stages have been broadly evaluated. The potential application of these nanodrugs in onco-therapies has been assessed by studying in vitro biocompatibility (interactions with environment) by proteomics characterization the determination of protein corona in different proximal fluids (human plasma, rabbit plasma and fetal bovine serum),. Moreover, protein labeling and LC–MS/MS analysis provided more than 4000 proteins de novo synthetized as consequence of the nanodrugs presence defending cell signaling in different tumor cell types (data available via ProteomeXchanges with identified PXD026615). Further in vivo studies have provided a more integrative view of the biopharmaceutical perspectives of IONPs. Conclusions Pharmacological proteomic profile different behavior between species and different affinity of protein coating layers (soft and hard corona). Also, intracellular signaling exposed differences between tumor cell lines studied. First approaches in animal model reveal the potential of theses NPs as drug delivery vehicles and confirm cisplatin compounds as strengthened antitumoral agents.
Supplementary Information The online version contains supplementary material available at 10.1186/s12951-022-01546-y.
Collapse
Affiliation(s)
- Ángela-Patricia Hernández
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,Department of Pharmaceutical Sciences. Organic Chemistry Section. Faculty of Pharmacy, University of Salamanca, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Ania Micaelo
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Rafael Piñol
- INMA, Institute of Nanoscience and Materials of Aragon, CSIC-University of Zaragoza, 50018, Saragossa, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Marina L García-Vaquero
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - José J Aramayona
- Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Julio J Criado
- Department of Inorganic Chemistry, Faculty of Chemical Sciences, Plaza de los Caídos S/N, 37008, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Emilio Rodriguez
- Department of Inorganic Chemistry, Faculty of Chemical Sciences, Plaza de los Caídos S/N, 37008, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - José Ignacio Sánchez-Gallego
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Alicia Landeira-Viñuela
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Pablo Juanes-Velasco
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Paula Díez
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Rafael Góngora
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Ricardo Jara-Acevedo
- ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Alberto Orfao
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Javier Miana-Mena
- Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - María Jesús Muñoz
- Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Sergio Villanueva
- Department of Pharmacology and Physiology, University of Zaragoza, Zaragoza, Spain.,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain
| | - Ángel Millán
- INMA, Institute of Nanoscience and Materials of Aragon, CSIC-University of Zaragoza, 50018, Saragossa, Spain. .,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain.
| | - Manuel Fuentes
- Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre, (IBMCC/CSIC/USAL/IBSAL), University of Salamanca-CSIC, IBSAL, Campus Miguel de Unamuno s/n, 37007, Salamanca, Spain. .,ImmunoStep, SL, Edificio Centro de Investigación del Cáncer, University of Salamanca, Avda. Coimbra s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain. .,Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007, Salamanca, Spain.
| |
Collapse
|
5
|
Novohradsky V, Markova L, Kostrhunova H, Svitelova M, Kasparkova J, Barbanente A, Papadia P, Margiotta N, Hoeschele JD, Brabec V. Pt( ii) complex containing the 1 R,2 R enantiomer of trans-1,2-diamino-4-cyclohexene ligand effectively and selectively inhibits the viability of aggressive pancreatic adenocarcinoma cells and alters their lipid metabolism. Inorg Chem Front 2022. [DOI: 10.1039/d2qi00778a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
New compounds structurally derived from oxaliplatin exhibit high potency in malignant pancreatic adenocarcinoma cells. Their mechanism of antiproliferative action in pancreatic cancer cells involves inhibition of de novo lipid synthesis.
Collapse
Affiliation(s)
- Vojtech Novohradsky
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - Lenka Markova
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - Hana Kostrhunova
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - Marie Svitelova
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - Jana Kasparkova
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
- Department of Biophysics, Faculty of Science, Palacky University in Olomouc, Slechtitelu 27, CZ-78371 Olomouc, Czech Republic
| | - Alessandra Barbanente
- Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Via Orabona, 4, I-70125 Bari, Italy
| | - Paride Papadia
- Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, 73100 Lecce, Italy
| | - Nicola Margiotta
- Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Via Orabona, 4, I-70125 Bari, Italy
| | - James D. Hoeschele
- Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, USA
| | - Viktor Brabec
- Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| |
Collapse
|